PL2194043T3 - Sposoby - Google Patents

Sposoby

Info

Publication number: PL2194043T3
Authority: PL; Poland
Prior art keywords: processes
Prior art date: 2005-08-19

Application number

PL10155058T

Other languages

English (en)

Inventor

Gerald J Tanoury

Minzhang Chen

John E Cochran

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-19

Filing date

2006-08-18

Publication date

2014-07-31

2006-08-18 Application filed by Vertex Pharma filed Critical Vertex Pharma

2014-07-31 Publication of PL2194043T3 publication Critical patent/PL2194043T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Virology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Pyrrole Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL10155058T 2005-08-19 2006-08-18 Sposoby PL2194043T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US70996405P	2005-08-19	2005-08-19
US81004206P	2006-06-01	2006-06-01
EP10155058.0A EP2194043B1 (en)	2005-08-19	2006-08-18	Processes
EP06813568A EP1934179B1 (en)	2005-08-19	2006-08-18	Processes and intermediates

Publications (1)

Publication Number	Publication Date
PL2194043T3 true PL2194043T3 (pl)	2014-07-31

Family

ID=37708299

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL06813568T PL1934179T4 (pl)	2005-08-19	2006-08-18	Sposoby i związki pośrednie
PL10155058T PL2194043T3 (pl)	2005-08-19	2006-08-18	Sposoby
PL385229A PL385229A1 (pl)	2005-08-19	2006-08-18	Sposoby i związki pośrednie

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL06813568T PL1934179T4 (pl)	2005-08-19	2006-08-18	Sposoby i związki pośrednie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL385229A PL385229A1 (pl)	2005-08-19	2006-08-18	Sposoby i związki pośrednie

Country Status (24)

Country	Link
US (3)	US7776887B2 (pl)
EP (4)	EP2364970A1 (pl)
JP (1)	JP5203203B2 (pl)
KR (4)	KR20130110236A (pl)
CN (2)	CN102382170A (pl)
AR (1)	AR058025A1 (pl)
AT (1)	ATE463480T1 (pl)
AU (1)	AU2006279357B2 (pl)
BR (1)	BRPI0615029A2 (pl)
CA (1)	CA2619659A1 (pl)
CY (2)	CY1110214T1 (pl)
DE (1)	DE602006013492D1 (pl)
DK (2)	DK1934179T3 (pl)
ES (2)	ES2344156T3 (pl)
IL (2)	IL189585A (pl)
NZ (3)	NZ604087A (pl)
PL (3)	PL1934179T4 (pl)
PT (2)	PT1934179E (pl)
RU (2)	RU2446171C2 (pl)
SG (1)	SG2014013338A (pl)
SI (2)	SI2194043T1 (pl)
TW (2)	TW201245149A (pl)
WO (1)	WO2007022459A2 (pl)
ZA (1)	ZA200801791B (pl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ298749B6 (cs) *	1996-10-18	2008-01-16	Vertex Pharmaceuticals Incorporated	Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
TW201127828A (en) *	2003-09-05	2011-08-16	Vertex Pharma	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN101277950B (zh) *	2005-08-02	2013-03-27	弗特克斯药品有限公司	丝氨酸蛋白酶抑制剂
US8399615B2 (en)	2005-08-19	2013-03-19	Vertex Pharmaceuticals Incorporated	Processes and intermediates
SG2014013338A (en)	2005-08-19	2014-06-27	Vertex Pharma	Processes and intermediates
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
CA2643688A1 (en)	2006-02-27	2007-08-30	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
US20070225297A1 (en)	2006-03-16	2007-09-27	Perni Robert B	Deuterated hepatitis C protease inhibitors
EP1993993A1 (en)	2006-03-16	2008-11-26	Vertex Pharmaceuticals Incorporated	Processes and intermediates for preparing steric compounds
US8222427B2 (en) *	2006-12-15	2012-07-17	Merck Sharp & Dohme Corp.	Bisulfite purification of an alpha-keto amide
EP2134717A2 (en) *	2007-02-27	2009-12-23	Vertex Pharmceuticals Incorporated	Inhibitors of serine proteases
MX2009009182A (es) *	2007-02-27	2009-09-04	Vertex Pharma	Co-cristales y composiciones farmaceuticas que los comprenden.
NZ583699A (en) *	2007-08-30	2012-04-27	Vertex Pharma	Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
WO2009114633A1 (en) *	2008-03-12	2009-09-17	Virobay, Inc.	Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
WO2009152474A2 (en) *	2008-06-13	2009-12-17	Virobay, Inc.	Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
AU2009271325A1 (en)	2008-06-24	2010-01-21	Merck Sharp & Dohme Corp.	Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
MX2012009927A (es) *	2010-02-25	2012-10-05	Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg	Proceso para la preparacion de alfa-aciloxibeta-formamida amidas.
WO2011153423A2 (en)	2010-06-03	2011-12-08	Vertex Pharmaceuticals Incorporated	Processes and intermediates
CN102167680B (zh) *	2011-03-23	2014-07-02	合亚医药科技（上海）有限公司	八氢环戊基并[c]吡咯羧酸衍生物的制备方法
EP2707347A1 (en) *	2011-05-13	2014-03-19	Vertex Pharmaceuticals Inc.	Processes and intermediates
WO2012158515A1 (en) *	2011-05-13	2012-11-22	Vertex Phamaceuticals Incorporated	Process for the preparation of protease inhibitors
JP2013010738A (ja) *	2011-05-31	2013-01-17	Sumitomo Chemical Co Ltd	エステル化合物の製造方法
EP2583680A3 (en)	2011-10-21	2013-06-12	Abbvie Inc.	Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
SE1450130A1 (sv)	2011-10-21	2014-05-07	Abbvie Inc	Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
WO2013072328A1 (en)	2011-11-14	2013-05-23	Sanofi	Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN103183632A (zh) *	2011-12-29	2013-07-03	山东方明药业集团股份有限公司	一种3-氮杂双环辛烷盐酸盐的提纯方法
ITMI20120192A1 (it) *	2012-02-13	2013-08-14	Dipharma Francis Srl	Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
ITMI20120359A1 (it)	2012-03-07	2013-09-08	Dipharma Francis Srl	Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali
ITMI20121668A1 (it) *	2012-10-05	2014-04-06	Dipharma Francis Srl	Sintesi di un intermedio di un composto antivirale
ITMI20120391A1 (it) *	2012-03-13	2013-09-14	Dipharma Francis Srl	Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali
WO2013136265A1 (en)	2012-03-13	2013-09-19	Dipharma Francis S.R.L.	Synthesis of an intermediate of an antiviral compound
WO2013135870A1 (en)	2012-03-16	2013-09-19	Sandoz Ag	Process for the synthesis of telaprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof
ITMI20120608A1 (it)	2012-04-13	2013-10-14	Dipharma Francis Srl	Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
ITMI20120800A1 (it) *	2012-05-10	2013-11-11	Dipharma Francis Srl	Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali
AR091192A1 (es)	2012-05-30	2015-01-21	Chemo Iberica Sa	Procedimiento multicomponente para la preparacion de compuestos biciclicos
CN103450066B (zh) *	2012-05-30	2017-03-15	博瑞生物医药（苏州）股份有限公司	特拉匹韦中间体的制备方法
ITMI20120990A1 (it) *	2012-06-07	2013-12-08	Dipharma Francis Srl	Sintesi di un inibitore delle proteasi virali
IN2014DN10328A (pl) *	2012-06-20	2015-08-07	Sandoz Ag
WO2013189978A1 (en)	2012-06-20	2013-12-27	Sandoz Ag	PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR
WO2014019179A1 (zh) *	2012-08-01	2014-02-06	上海迪赛诺药业有限公司	特拉匹韦及其中间体的制备方法
WO2014033667A1 (en)	2012-08-30	2014-03-06	Ranbaxy Laboratories Limited	Process for the preparation of telaprevir
CN102875648B (zh) *	2012-09-26	2014-02-19	深圳翰宇药业股份有限公司	一种制备特拉匹韦的方法
WO2014053533A1 (en)	2012-10-05	2014-04-10	Sanofi	Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
ITMI20122036A1 (it)	2012-11-29	2014-05-30	Dipharma Francis Srl	Sintesi di un intermedio di un composto antivirale
US20160039871A1 (en) *	2012-12-21	2016-02-11	Sandoz Ag	Novel forms of telaprevir
WO2014096374A1 (en)	2012-12-21	2014-06-26	Sandoz Ag	Process for the synthesis of pyrrolidines and pyrroles
CN103936651B (zh) *	2013-01-18	2016-06-22	上海医药工业研究院	抗丙肝药物Boceprevir的中间体Ⅲ及其制备方法和应用
ITMI20130706A1 (it)	2013-04-30	2014-10-31	Dipharma Francis Srl	Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
CN103288671B (zh) *	2013-06-20	2014-10-29	上海步越化工科技有限公司	一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法
WO2014203208A1 (en)	2013-06-21	2014-12-24	Ranbaxy Laboratories Limited	Process for the preparation of telaprevir and intermediates thereof
WO2014203224A1 (en)	2013-06-21	2014-12-24	Ranbaxy Laboratories Limited	Process for the preparation of telaprevir and its intermediates
CN104292146B (zh) *	2013-06-24	2017-04-26	上海医药工业研究院	特拉匹韦中间体及其制备方法
CN103342656B (zh) *	2013-07-04	2015-04-08	苏州永健生物医药有限公司	特拉匹韦中间体的合成方法
CN103435532B (zh) *	2013-09-02	2015-07-08	苏州永健生物医药有限公司	波普瑞韦中间体的合成方法
WO2015036522A1 (en) *	2013-09-13	2015-03-19	Sandoz Ag	Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir
JP2016539931A (ja) *	2013-10-23	2016-12-22	株式会社カネカ	テトラペプチド化合物及びその製造方法
CN103664739B (zh) *	2013-12-10	2016-04-27	湖南科源生物制品有限公司	一种特拉匹韦中间体的制备方法
WO2016057931A1 (en)	2014-10-10	2016-04-14	The Research Foundation For The State University Of New York	Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN105646329A (zh) *	2014-11-28	2016-06-08	重庆圣华曦药业股份有限公司	一种制备特拉匹韦中间体的方法
CN105111129A (zh) *	2015-08-24	2015-12-02	上海合全药业股份有限公司	(1S,3aR,6aS)-八氢环戊烯并[C]吡咯-1-羧酸叔丁酯草酸盐的制备方法
CN105601556B (zh) *	2015-12-02	2018-11-13	镇江市高等专科学校	特拉匹韦双环吡咯烷中间体的制备方法
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP7584418B2 (ja)	2018-12-04	2024-11-15	ブリストル－マイヤーズスクイブカンパニー	多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
MX2022015207A (es)	2020-06-10	2023-02-13	Aligos Therapeutics Inc	Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
KR20240035513A (ko)	2021-07-09	2024-03-15	알리고스 테라퓨틱스 인코포레이티드	항바이러스 화합물
US12065428B2 (en)	2021-09-17	2024-08-20	Aligos Therapeutics, Inc.	Anti-viral compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3211676A1 (de) *	1982-03-30	1983-10-06	Hoechst Ag	Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US5468858A (en) *	1993-10-28	1995-11-21	The Board Of Regents Of Oklahoma State University Physical Sciences	N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
JPH0967344A (ja) *	1995-09-05	1997-03-11	Koei Chem Co Ltd	光学活性ｎ−ベンジルオキシカルボニルピペコリン酸の製造方法
JPH11513890A (ja)	1996-05-10	1999-11-30	シェーリングコーポレイション	Ｃ型肝炎ウイルスｎｓ３プロテアーゼの合成インヒビター
JP3863230B2 (ja)	1996-08-16	2006-12-27	株式会社カネカ	β−アミノ−α−ヒドロキシ酸誘導体の製造方法
CZ298749B6 (cs)	1996-10-18	2008-01-16	Vertex Pharmaceuticals Incorporated	Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
GB9707659D0 (en)	1997-04-16	1997-06-04	Peptide Therapeutics Ltd	Hepatitis C NS3 Protease inhibitors
US6767991B1 (en)	1997-08-11	2004-07-27	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C inhibitor peptides
DK1003775T3 (da)	1997-08-11	2005-05-30	Boehringer Ingelheim Ca Ltd	Hepatitis C-inhibitorpeptider
WO1999007734A2 (en)	1997-08-11	1999-02-18	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor peptide analogues
IT1299134B1 (it)	1998-02-02	2000-02-29	Angeletti P Ist Richerche Bio	Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
EP1066247B1 (en)	1998-03-31	2006-11-22	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en)	1998-06-10	1998-08-05	Angeletti P Ist Richerche Bio	Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
DE19836514A1 (de)	1998-08-12	2000-02-17	Univ Stuttgart	Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
GB9825946D0 (en)	1998-11-26	1999-01-20	Angeletti P Ist Richerche Bio	Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
AU2943400A (en)	1999-03-12	2000-10-04	Ajinomoto Co., Inc.	Process for the preparation of alpha-aminoketone derivatives
UA74546C2 (en)	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en)	1999-07-26	2006-10-17	Bristol-Myers Squibb Company	Lactam inhibitors of Hepatitis C virus NS3 protease
WO2001007407A1 (en)	1999-07-26	2001-02-01	Bristol-Myers Squibb Pharma Company	Lactam inhibitors of hepatitis c virus ns3 protease
EP1261611A2 (en)	2000-02-29	2002-12-04	Bristol-Myers Squibb Pharma Company	Inhibitors of hepatitis c virus ns3 protease
WO2001066144A2 (en) *	2000-03-08	2001-09-13	Rhode Island Hospital, A Lifespan Partner	Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
DE60111509T2 (de)	2000-04-03	2006-05-11	Vertex Pharmaceuticals Inc., Cambridge	Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
JP4748911B2 (ja)	2000-04-05	2011-08-17	シェーリングコーポレイション	Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
CN1432022A (zh)	2000-04-19	2003-07-23	先灵公司	含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
US7244721B2 (en) *	2000-07-21	2007-07-17	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es)	2000-07-21	2004-02-04	Schering Corp	Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
RU2003105221A (ru)	2000-07-21	2004-09-20	Шеринг Корпорейшн (US)	Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
AR029851A1 (es)	2000-07-21	2003-07-16	Dendreon Corp	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
CZ303213B6 (cs)	2000-07-21	2012-05-23	Schering Corporation	Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en)	2000-10-23	2005-01-25	Bristol-Myers Squibb Company	Peptide inhibitors of Hepatitis C virus NS3 protein
CA2429359A1 (en)	2000-11-20	2002-08-08	Bristol-Myers Squibb Company	Hepatitis c tripeptide inhibitors
US6727366B2 (en)	2000-12-13	2004-04-27	Bristol-Myers Squibb Pharma Company	Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
AU2002230763A1 (en)	2000-12-13	2008-01-03	Bristol-Myers Squibb Pharma Company	Inhibitors of hepatitis c virus ns3 protease
US6653295B2 (en)	2000-12-13	2003-11-25	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus NS3 protease
GB0107924D0 (en)	2001-03-29	2001-05-23	Angeletti P Ist Richerche Bio	Inhibitor of hepatitis C virus NS3 protease
JP4455056B2 (ja)	2001-07-11	2010-04-21	バーテックスファーマシューティカルズインコーポレイテッド	架橋二環式セリンプロテアーゼ阻害剤
EP1441720B8 (en)	2001-10-24	2012-03-28	Vertex Pharmaceuticals Incorporated	Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
US20040180815A1 (en)	2003-03-07	2004-09-16	Suanne Nakajima	Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
WO2004072243A2 (en)	2003-02-07	2004-08-26	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis c serine protease inhibitors
BRPI0414814A (pt) *	2003-09-26	2006-11-14	Schering Corp	inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
US7365092B2 (en)	2003-10-10	2008-04-29	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2328589T3 (es)	2004-02-27	2009-11-16	Schering Corporation	Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
SG2014013338A (en)	2005-08-19	2014-06-27	Vertex Pharma	Processes and intermediates
EP2494991A1 (en)	2007-05-04	2012-09-05	Vertex Pharmaceuticals Incorporated	Combination therapy for the treatment of HCV infection

2006
- 2006-08-18 SG SG2014013338A patent/SG2014013338A/en unknown
- 2006-08-18 PT PT06813568T patent/PT1934179E/pt unknown
- 2006-08-18 SI SI200631745T patent/SI2194043T1/sl unknown
- 2006-08-18 TW TW101126397A patent/TW201245149A/zh unknown
- 2006-08-18 CA CA002619659A patent/CA2619659A1/en not_active Abandoned
- 2006-08-18 EP EP11150041A patent/EP2364970A1/en not_active Withdrawn
- 2006-08-18 RU RU2008110479/04A patent/RU2446171C2/ru not_active IP Right Cessation
- 2006-08-18 AU AU2006279357A patent/AU2006279357B2/en not_active Ceased
- 2006-08-18 ES ES06813568T patent/ES2344156T3/es active Active
- 2006-08-18 DK DK06813568.0T patent/DK1934179T3/da active
- 2006-08-18 BR BRPI0615029-2A patent/BRPI0615029A2/pt not_active IP Right Cessation
- 2006-08-18 WO PCT/US2006/032481 patent/WO2007022459A2/en not_active Ceased
- 2006-08-18 EP EP11150039A patent/EP2357170A1/en not_active Withdrawn
- 2006-08-18 AT AT06813568T patent/ATE463480T1/de active
- 2006-08-18 ES ES10155058.0T patent/ES2449268T3/es active Active
- 2006-08-18 KR KR1020137024964A patent/KR20130110236A/ko not_active Ceased
- 2006-08-18 PL PL06813568T patent/PL1934179T4/pl unknown
- 2006-08-18 US US11/506,550 patent/US7776887B2/en not_active Expired - Fee Related
- 2006-08-18 CN CN2011102403592A patent/CN102382170A/zh active Pending
- 2006-08-18 PL PL10155058T patent/PL2194043T3/pl unknown
- 2006-08-18 CN CN2006800384541A patent/CN101291909B/zh not_active Expired - Fee Related
- 2006-08-18 EP EP10155058.0A patent/EP2194043B1/en not_active Not-in-force
- 2006-08-18 PL PL385229A patent/PL385229A1/pl not_active Application Discontinuation
- 2006-08-18 DE DE602006013492T patent/DE602006013492D1/de active Active
- 2006-08-18 JP JP2008527189A patent/JP5203203B2/ja not_active Expired - Fee Related
- 2006-08-18 AR ARP060103610A patent/AR058025A1/es unknown
- 2006-08-18 EP EP06813568A patent/EP1934179B1/en not_active Not-in-force
- 2006-08-18 DK DK10155058.0T patent/DK2194043T3/da active
- 2006-08-18 KR KR1020137005426A patent/KR20130038947A/ko not_active Ceased
- 2006-08-18 NZ NZ604087A patent/NZ604087A/en not_active IP Right Cessation
- 2006-08-18 KR KR1020147013418A patent/KR20140069370A/ko not_active Ceased
- 2006-08-18 NZ NZ566049A patent/NZ566049A/en not_active IP Right Cessation
- 2006-08-18 NZ NZ593214A patent/NZ593214A/xx not_active IP Right Cessation
- 2006-08-18 TW TW095130511A patent/TWI391376B/zh not_active IP Right Cessation
- 2006-08-18 PT PT101550580T patent/PT2194043E/pt unknown
- 2006-08-18 SI SI200630710T patent/SI1934179T1/sl unknown
2008
- 2008-02-18 IL IL189585A patent/IL189585A/en not_active IP Right Cessation
- 2008-02-25 ZA ZA200801791A patent/ZA200801791B/xx unknown
- 2008-03-18 KR KR1020087006558A patent/KR101474405B1/ko not_active Expired - Fee Related
2010
- 2010-03-15 US US12/661,319 patent/US8637457B2/en not_active Expired - Fee Related
- 2010-07-05 CY CY20101100613T patent/CY1110214T1/el unknown
2011
- 2011-11-29 RU RU2011148615/04A patent/RU2011148615A/ru not_active Application Discontinuation
2013
- 2013-10-07 IL IL228770A patent/IL228770A0/en unknown
- 2013-12-17 US US14/109,631 patent/US20140107318A1/en not_active Abandoned
2014
- 2014-02-25 CY CY20141100149T patent/CY1114916T1/el unknown

Also Published As

Publication number	Publication date
EP2194043B1 (en)	2013-12-25
EP1934179A2 (en)	2008-06-25
AU2006279357B2 (en)	2012-05-31
PT1934179E (pt)	2010-07-12
IL189585A (en)	2013-10-31
HK1145022A1 (en)	2011-03-25
KR20140069370A (ko)	2014-06-09
IL228770A0 (en)	2013-12-31
JP2009504780A (ja)	2009-02-05
TW201245149A (en)	2012-11-16
CN101291909A (zh)	2008-10-22
CA2619659A1 (en)	2007-02-22
EP2194043A3 (en)	2010-11-24
CN101291909B (zh)	2012-09-05
BRPI0615029A2 (pt)	2009-06-16
SI2194043T1 (sl)	2014-04-30
AR058025A1 (es)	2008-01-23
US8637457B2 (en)	2014-01-28
TW200800889A (en)	2008-01-01
CN102382170A (zh)	2012-03-21
EP2364970A1 (en)	2011-09-14
KR101474405B1 (ko)	2014-12-23
KR20080047396A (ko)	2008-05-28
PT2194043E (pt)	2014-03-04
RU2011148615A (ru)	2013-06-10
DK2194043T3 (da)	2014-01-20
WO2007022459A2 (en)	2007-02-22
CY1110214T1 (el)	2015-01-14
ES2344156T3 (es)	2010-08-19
US20100174077A1 (en)	2010-07-08
TWI391376B (zh)	2013-04-01
AU2006279357A1 (en)	2007-02-22
WO2007022459A3 (en)	2008-02-28
EP2357170A1 (en)	2011-08-17
JP5203203B2 (ja)	2013-06-05
RU2446171C2 (ru)	2012-03-27
EP1934179B1 (en)	2010-04-07
EP2194043A2 (en)	2010-06-09
CY1114916T1 (el)	2016-12-14
PL385229A1 (pl)	2008-09-29
KR20130038947A (ko)	2013-04-18
PL1934179T3 (pl)	2010-09-30
SG2014013338A (en)	2014-06-27
PL1934179T4 (pl)	2014-03-31
SI1934179T1 (sl)	2010-08-31
IL189585A0 (en)	2008-08-07
HK1122801A1 (en)	2009-05-29
ATE463480T1 (de)	2010-04-15
ES2449268T3 (es)	2014-03-19
ZA200801791B (en)	2008-12-31
US20140107318A1 (en)	2014-04-17
NZ604087A (en)	2014-07-25
RU2008110479A (ru)	2009-09-27
US20070087973A1 (en)	2007-04-19
NZ566049A (en)	2011-07-29
NZ593214A (en)	2013-02-22
KR20130110236A (ko)	2013-10-08
DE602006013492D1 (de)	2010-05-20
DK1934179T3 (da)	2010-08-09
US7776887B2 (en)	2010-08-17

Publication	Publication Date	Title
SI2194043T1 (sl)	2014-04-30	Postopki
DE502006001600D1 (en)	2008-10-30	Pyrazolylcarboxanilide
DE602006018441D1 (en)	2011-01-05	Arabinofuranosidasen
DE602006018627D1 (en)	2011-01-13	Cholesterol-absorptionsinhibitor
DE602006017073D1 (en)	2010-11-04	Aspartylproteasehemmer
DK1866498T3 (en)	2020-08-17	C-profil
EP1871379A4 (en)	2010-06-02	CYANOARYLAMINE
DE602006003064D1 (en)	2008-11-20	Tripeptid- und tetrapeptid-thioether
DE602006009492D1 (en)	2009-11-12	Fluidmaschinen
DE602006014261D1 (en)	2010-06-24	Benzimidazolverbindungen
DE602006009835D1 (en)	2009-11-26	Nthalten
DE602006016951D1 (en)	2010-10-28	2-cyanoacrylatzusammensetzung
EP1951848A4 (en)	2011-12-07	VIESEL
DE502005007477D1 (en)	2009-07-23	Delta-sigma-modulator
EP1871655A4 (en)	2012-12-26	TRIGGER OPERATION FOR SIDE DRIVE
EP1934350A4 (en)	2009-08-19	POLYOLEOSINE
DE602006021558D1 (en)	2011-06-09	Modulare montgomery-multiplikationseinrichtung
EP1871796A4 (en)	2009-01-14	VESICULINE
EP1865780A4 (en)	2011-04-27	MINI OVEN
DE602006015303D1 (en)	2010-08-19	Lecknachweisflicken
DE502006002219D1 (en)	2009-01-08	Rotationspumpe
DE502006004337D1 (en)	2009-09-03	Strangführungsrolle
EP1954133A4 (en)	2010-11-24	PYRROLIDINANILINE
EG25704A (en)	2012-05-23	Safe-pool
AU4036P (en)	2010-06-22	Dottie Calathea roseo-picta